Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer

by Zacks Equity Research

AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.

Clovis Posts Data on Rubraca Study for Pancreatic Cancer

by Zacks Equity Research

Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.

Advaxis Up on Positive Early-Stage Immunotherapy Study Data

by Zacks Equity Research

Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

Implied Volatility Surging for Clovis (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

Why Is Clovis (CLVS) Down 21% Since Last Earnings Report?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover

by Zacks Equity Research

Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.

AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

by Zacks Equity Research

AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

by Zacks Equity Research

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

by Zacks Equity Research

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

by Sanghamitra Saha

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Immunomedics Gets CRL From FDA for Breast Cancer Candidate

by Zacks Equity Research

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Immunomedics Enters Into Supply Deal for Breast Cancer Drug

by Zacks Equity Research

Immunomedics (IMMU) entered into a long-term master supply agreement for lead candidate, sacituzumab govitecan.

AstraZeneca's (AZN) Lynparza Gets FDA Nod in 1st Line Setting

by Zacks Equity Research

AstraZeneca's (AZN) Lynparza receives FDA approval for first-line maintenance treatment of advanced ovarian cancer.

Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Clovis (SFIX) stock based on the movements in the options market lately.

Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher

by Zacks Equity Research

Clovis Oncology (CLVS) shares rose nearly 7% in the last trading session, amid huge volumes.

Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%

by Zacks Equity Research

Glaxo (GSK) announces definitive deal to buy TESARO.

TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer

by Zacks Equity Research

TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.

Clovis (CLVS) Up 45.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up

by Zacks Equity Research

Clovis Oncology's (CLVS) shares rise more than 5% following the issuance of a new patent for Rubraca in the United States for claims related to methods of treating cancer with its high dosage strength.

TESARO Shares Rally on Rumors of Potential Acquisition Offer

by Zacks Equity Research

Per a Bloomberg report, TESARO (TSRO) may have received an acquisition offer. Shares rally on rumors.

Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA

by Zacks Equity Research

PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.

AstraZeneca's Lynparza Gets Priority Review in 1st Line Use

by Zacks Equity Research

AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.